Controversies in the management of patent ductus arteriosus

NeoReviews

Volumn 9, Issue 10, 2008, Pages

  Gien, Jason ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77149141142     PISSN: None     EISSN: 15269906     Source Type: Journal    
DOI: 10.1542/neo.9-10-e477     Document Type: Article

References (37)

1. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely low birth weight infants. N Engl J Med 2001;344:1966-1972
2. Clyman RI. Mechanisms regulating the ductus arteriosus. Biol Neonate. 2006;89:330-335
3. Cotton RB, Stahlman MT, Berder HW, Graham TP, Catterton WZ, Kover I. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. J Pediatr. 1978; 93:647-651
4. Cotton RB, Hickey DE, Graham TP, Stahlman MT. Effect of early indomethacin on ventilatory status of preterm infants with symptomatic patent ductus arteriosus. Pediatr Res. 1980;14:442
5. Mahony L, Carnero V, Brett C, Heymann MA, Clyman RI. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants. N Engl J Med. 1982;306:506-510
6. Merritt TA, Harris JP, Roghmann K, Wood B, Campanella V, Alexson C. Early closure of patent ductus arteriosus in very low-birth weight infants: a controlled trial. J Pediatr. 1981;99:281-286
7. Gerhardt T, Bancalari E. Lung compliance in newborns with patent ductus arteriosus before and after surgical ligation. Biol Neonate 1980;38:96-100
8. Bancalari E, Claure N, Gonzalez A. Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate. 2005;88: 192-201
9. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr. 1995;126:605-610
10. Krauss AN, Fatica N, Lewis BS, et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. Am J Dis Child. 1989;143:78-81
11. Alpan G, Mauray F, Clyman RI. Effect of patent ductus arteriosus on water accumulation and protein permeability in the premature lungs of mechanically ventilated premature lambs. Pediatr Res. 1989;26:570-575
12. Perez Fontan JJ, Clyman RI, Mauray F, Heymann MA, Roman C. Respiratory effects of a patent ductus arteriosus in premature newborn lambs. J Appl Physiol. 1987;63:2315-2324
13. Laughon MM, Simmons MA, Bose CL. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? Curr Opin Pediatr. 2004;16:146-151
14. McCurnin DC, Yoder BA, Coalson J, et al. Effect of ductus ligation on cardiopulmonary function in premature baboons. Am J Respir Crit Care Med. 2005;172:1569-1574
15. Schmidt B, Roberts RS, Fanaroff A, et al; TIPP investigators. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr. 2006; 148:730-734
16. Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2002;3:CD000174
17. Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006;25:CD004213
18. Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr. 2005;164:135-140
19. Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of a patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2007;3:CD003481
20. Sekar KC, Corff KE. Treatment of patent ductus arteriosus: indomethacin or ibuprofen? J Perinatol. 2008;28(suppl 1): S60-S62
21. Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2008;1: CD003951
22. Cassady G, Crouse DT, Kirklin JW, et al. A randomized, controlled trial of very early prophylactic ligation of the ductus arteriosus in babies who weighed 1000 g or less at birth. N Engl J Med. 1989;320:1511-1516
23. Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A, Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr. 2007;150:229-234
24. Chorne N, Leonard C, Piecuch R, Clyman RI. Patent ductus arteriosus and its treatment as risk factors for neonatal and neuro-developmental morbidity. Pediatrics. 2007;119:1165-1174
25. Surgery and the tiny baby: sensorineural outcome at 5 years of age. The Victorian Infant Collaborative Study Group. J Paediatr Child Health 1996;32:167-172
26. Herrman K, Bose C, Lewis K, Laughon M. Spontaneous closure of the patent ductus arteriosus in very low birth weight infants following discharge from the neonatal unit. Arch Dis Child Fetal Neonatal Ed. 2008 May 1. [Epub ahead of print]
27. Kluckow M, Evans N. Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation. J Pediatr 1995;127:774-779
28. Iyer P, Evans N. Re-evaluation of the left atrial-to-aortic root ratio as a marker of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 1994;70:F112-F117
29. Davis MW, Betheras FR, Swaminaathan M. A preliminary study of the application of the transductal velocity for assessing persistent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2000;82:F195-F199
30. Bhatt AB, Tank PD, Barmade KB, Damania KR. Abnormal Doppler flow velocimetry in the growth restricted foetus as a predictor for necrotising enterocolitis. J Postgrad Med. 2002;48: 182-185
31. Soregaroli M, Bonera R, Danti L, et al. Prognostic role of umbilical artery Doppler velocimetry in growth-restricted fetuses. J Matern Fetal Neonatal Med. 2002;11:199-203
32. Craigo SD, Beach ML, Harvey-Wilkes KB, D'Alton ME. Ultrasound predictors of neonatal outcome in intrauterine growth restriction. Am J Perinatol. 1996;13:465-471
33. Czernik C, Lemmer J, Metze B, Koehne PS, Mueller C, Obladen M. B-type natriuretic peptide to predict ductus intervention in infants 28 weeks. Pediatr Res 2008. [Epub ahead of print]
34. El-Khuffash AF, Barry D, Walsh K, Davis PG, Molloy EJ. Bio-chemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death of severe intraventricular haemorrhage. Arch Dis Child Fetal Neonatal Ed. 2008. [Epub ahead of print]
35. Farombi-Oghuvbu IO, Matthews T, Mayne PD, Guerin H, Corcoran D. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2008;93:F257-F260
36. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, L'Ecuyer T. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol. 2005;25:709-713
37. Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2007;2: CD003480